Based on the results obtained from TIMER2.0, we found that the expression of CLU was significantly reduced in the tumor tissue of a majority of cancers compared to their matched normal controls, such as bladder urothelial carcinoma (BLCA), breast invasive carcinoma (BRCA), and colorectal (COAD and READ) and lung (LUSC and LUAD) cancers. The gene discussed is CLU; the disease is cancer.